Development and Validation of an LC-MS/MS Method to Quantify Gilteritinib and Its Clinical Application in Patients With FLT3 Mutation–Positive Acute Myelogenous Leukemia
Sign Up to like & getrecommendations! Published in 2022 at "Therapeutic Drug Monitoring"
DOI: 10.1097/ftd.0000000000000971
Abstract: Background: Gilteritinib, a novel oral tyrosine kinase inhibitor, is used to treat acute myeloid leukemia (AML) with FMS-like tyrosine kinase-3 (FLT3) mutations. Therapeutic drug monitoring (TDM) of gilteritinib is important for improving clinical outcomes and… read more here.
Keywords: development validation; gilteritinib clinical; leukemia; method ... See more keywords